SCHEMBL8958230

SCHEMBL8958230

CC1(C2CCCCC2)NC(=O)NC1=O

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.36
MMP13 P45452 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TDP1 Q9NUW8 1/20 0.35
HPGD P15428 1/20 0.35
MAPK1 P28482 1/20 0.35
ADAMTS5 Q9UNA0 2/20 0.33
HSD11B1 P28845 6/20 0.32
APP P05067 1/20 0.32
BACE1 P56817 1/20 0.32
BACE2 Q9Y5Z0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15974332 1.00 GAA (0.36) GAAMMP13RAB9ASMN1; SMN2TDP1
SCHEMBL15974011 0.98 GAA (0.36) GAAMMP13RAB9ASMN1; SMN2TDP1
SCHEMBL542745 0.94 TDP1 (0.36) GAAMMP13RAB9ASMN1; SMN2TDP1
SCHEMBL542184 0.90 ADAMTS7 (0.35) TDP1ADAMTS5
SCHEMBL8686431 0.87 APP (0.35) GAAMMP13RAB9ASMN1; SMN2HSD11B1
SCHEMBL8686102 0.87 APP (0.35) GAAMMP13RAB9ASMN1; SMN2HSD11B1
SCHEMBL15973968 0.80 RAB9A (0.32) RAB9ATDP1
SCHEMBL15974145 0.76 TDP1 (0.33) GAATDP1HPGDMAPK1
SCHEMBL15974003 0.76 ABCB1 (0.34) GAAHPGD
SCHEMBL11623733 0.75 GAA (0.37) GAAMMP13RAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4745189-A Method of preparing N-halogenated organic heterocyclic compounds ETHYL CORPORATION (US) 1988-05-17 US claimed
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FORMA THERAPEUTICS, INC. 2021-07-15 US disclosed
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 US disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 EP disclosed
US-10421727-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2019-09-24 US disclosed
EP-3461816-A1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2019-04-03 EP disclosed
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED 2017-12-28 US disclosed
US-9840471-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2017-12-12 US disclosed
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. 2015-12-31 US disclosed
EP-2958897-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2015-12-30 EP disclosed
WO-2014130582-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. (US) 2014-08-28 WO disclosed
US-5559233-A 3-/P-PHENYLBENZYL/IMIDAZOLONES AND PYRIMIDONES SANOFI (FR) 1996-09-24 US disclosed
US-5352788-A Angiotensin antagonist ELF SANOFI (FR) 1994-10-04 US disclosed
US-5274104-A N-substituted heterocyclic derivatives useful in the treatment of cardiovascular disorders ELF SANOFI, A FRENCH CORP. (FR) 1993-12-28 US disclosed
US-5270317-A N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present ELF SANOFI (FR) 1993-12-14 US disclosed
US-5268375-A Dinitrogen heterocyclic derivatives N-substituted by a biphenylmethyl group, and the pharmaceutical compositions in which they are present ELF SANOFI (FR) 1993-12-07 US disclosed
US-4745189-A Method of preparing N-halogenated organic heterocyclic compounds ETHYL CORPORATION (US) 1988-05-17 US disclosed
US-4105450-A SPECTRALLY SENSITIZED POSITIVE LIGHT-SENSITIVE O-QUINONE DIAZIDE CONTAINING COMPOSITION FUJI PHOTO FILM CO., LTD. (JP) 1978-08-08 US disclosed
US-4071477-A CASTING AND LAMINATING RESINS CIBA-GEIGY CORPORATION (US) 1978-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421727-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 GAA 3493/4885MMP13 4845/4885RAB9A 1312/4885
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM7, TRPA1 GAA 3493/4885MMP13 4845/4885RAB9A 1312/4885
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM7, TRPA1 GAA 3493/4885MMP13 4845/4885RAB9A 1312/4885
US-11028052-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 GAA 3493/4885MMP13 4845/4885RAB9A 1312/4885
US-20210214323-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN FASN, FABP1, SCD GAA 1024/4885MMP13 3082/4885RAB9A 2631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.